8-K: MIRA Pharmaceuticals Appoints Fractional CFO

MIRA Pharmaceuticals has appointed Andriy Mushak as its new fractional Chief Financial Officer, effective June 6, 2026.

Summary

• Alan Weichselbaum is stepping down as Chief Financial Officer of MIRA Pharmaceuticals, effective June 6, 2026.
• Andriy Mushak, a CPA and partner at LMAM Consulting Group, LLC, has been appointed as the new fractional Chief Financial Officer.
• The appointment is part of a consulting agreement where MIRA will pay $6,000 per month for financial leadership services.
• The transition is not the result of any disagreement regarding company operations, policies, or practices.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral administrative update; while the appointment of an experienced CPA is positive, the move to a fractional CFO role suggests a lean operational strategy.

Positives

• The appointment of a CPA with over 20 years of experience in SEC reporting and financial audits provides stability in financial oversight.
• The transition is amicable, with no reported disagreements between the outgoing CFO and the company.
• The fractional CFO model provides cost-effective access to senior financial expertise for a smaller firm.

Negatives

• The departure of a full-time CFO in favor of a fractional arrangement may signal a shift in administrative structure or cost-cutting measures.
• The company is relying on an external consultant rather than an internal executive for critical financial reporting and compliance functions.

Risks

• Reliance on a fractional CFO may limit the depth of internal financial leadership compared to a full-time executive.
• Potential for conflicts of interest, as the consultant is permitted to provide services to other clients in the pharmaceutical and life sciences sectors.
• The company remains responsible for all financial disclosures and internal controls, despite the consultant's advisory role.

Future Outlook

The company intends to utilize the fractional CFO to support regulatory, capital-markets, and strategic-growth objectives, focusing on audit readiness and financial discipline.

Management Comments

• The departure of Mr. Weichselbaum was not the result of any disagreement with the Company on any matter relating to the Company's operations, policies, or practices.

Industry Context

StockSavvy.ai notes that the shift toward fractional executive roles is becoming increasingly common among small-cap biotech and pharmaceutical firms looking to manage overhead while maintaining high-level SEC compliance and audit readiness.

Comparison to Industry Standards

• The use of a fractional CFO is a standard practice for emerging growth companies on the Nasdaq Capital Market to balance professional financial oversight with operational cost efficiency.
• The compensation structure is consistent with market rates for fractional financial advisory services for companies of similar size and stage.

Management Changes

Corporate Governance

Legal Proceedings

• None mentioned.

Related Party Transactions

• None mentioned.

Stakeholder Impact

• Shareholders may view the move to a fractional CFO as a cost-saving measure, though it may raise questions regarding the company's long-term executive staffing strategy.

Next Steps

• Integration of Andriy Mushak into the company's financial reporting and audit processes.
• Ongoing support for capital-markets readiness and SEC compliance.

Key Dates

Keywords

MIRA Pharmaceuticals, Fractional CFO, SEC reporting, Corporate governance, Executive appointment, Financial compliance